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Progression of coronary artery calcification in diabetics with
and without chronic kidney disease.
Background. Rapid progression of coronary artery calcifica-
tion (CAC) has been reported among individuals with end-stage
renal disease (ESRD). There is limited information on the pro-
gression of CAC during earlier stages of diabetic chronic kidney
disease (CKD).
Methods. In a prospective, cohort study of type 2 diabetic
individuals (N = 90; normoalbuminuric diabetic controls, 30; di-
abetic nephropathy, DN, 60), electron-beam computed tomog-
raphy (EBCT) was repeated at an average interval of 19 months.
All scan images were acquired at end-systole to minimize in-
terscan variability. In order to eliminate the dependence of the
residual error from interscan variability on baseline CAC scores,
square root transformed CAC scores were used for analyses of
progression of coronary calcification.
Results. Repeat EBCT scans were completed in 68 subjects
(diabetic controls: 23; DN: 45). There was a highly significant
relationship between the proportion of subjects with progres-
sive CAC and renal disease—DN who progressed to ESRD,
80%; DN who did not progress to ESRD, 30%; and diabetic
controls, 13% (P < 0.001). Similarly, the magnitude of change
was significantly related to renal disease (DN who progressed to
ESRD > DN who did not progress to ESRD > diabetic controls,
P < 0.001). Using logistic regression and controlling for non-
dialyzed DN, ESRD and inter-scan interval, advanced age was
the only significant variable associated with progression of CAC.
Finally, serum creatinine and baseline CAC score emerged as
independent predictors for the magnitude of increase in CAC.
Conclusion. Progression of CAC is apparent among individ-
uals with DN both before and after ESRD. However, the risk
factors associated with progression of CAC may differ at differ-
ent stages of CKD.
Key words: coronary artery calcification, progression, diabetic
nephropathy, cardiovascular disease, chronic kidney disease, mineral
metabolism.
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Over the last decade, sensitive tools like electron beam
computed tomography (EBCT) have demonstrated the
presence of coronary artery calcification (CAC), often
severe, in >80% of individuals with end-stage renal dis-
ease (ESRD) [1–3]. Evidence suggests that disordered
mineral metabolism or its therapies (viz., use of calcium
containing phosphate binders) contribute significantly to
this CAC [2–6]. More recent data indicates that CAC is
present at rather early stages of chronic kidney disease
(CKD) and among individuals with diabetic nephropa-
thy (DN), is often severe long before the need for main-
tenance dialysis therapy [7–10]. Furthermore, disordered
mineral metabolism or its therapies do not seem to con-
tribute to the prevalence or severity of CAC in the pre-
ESRD phase of CKD [8, 10].
In addition to cross-sectional studies, several longitu-
dinal studies have documented rapid progression of CAC
among individuals with ESRD and have attempted to de-
fine the risk factors associated with this rapid progression
[1, 2, 11, 12]. Moreover, at least two therapeutic interven-
tions have been shown to slow the rate of progression of
vascular calcification among individuals with ESRD [4,
13]. There are no comparable data on non-dialyzed dia-
betic patients with CKD or the effect of the presence of
DN on the rates of progression of CAC among individuals
with type 2 diabetes. Furthermore, inter-scan variability
is a major limitation in estimating rates of progression
of CAC using currently available technologies, including
EBCT [14–18]. Using conventional protocols of image
acquisition at 80% of the RR-interval, inter-scan vari-
ability of 30% or more has been reported [15–18]; newer
protocols have helped lower the average variability to
10% or less [19, 20]. Not withstanding these improve-
ments, inter-scan variability is not constant but depends
upon the baseline CAC score [15, 21, 22]. Thus, estimat-
ing rates of progression of CAC without accounting for
the inter-scan variability may lead to biased estimates of
the rates and risk factors associated with progression of
CAC.
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We undertook this study to test the hypothesis that
CAC is more likely to progress and the change in CAC
score will be greater among DN individuals, when com-
pared to duration-matched normoalbuminuric diabetic
controls (“diabetic controls”). Data were analyzed after
accounting for the error from inter-scan variability of the
EBCT scanning and thus, represent reliable estimates of
the rates of progression of CAC.
METHODS
Baseline and follow-up evaluations and definition
of diabetic controls and DN
This is a follow-up study of a cohort of individuals
with type 2 diabetes, with and without nephropathy [8,
23]. In order to minimize the confounding influence of
race/ethnicity, the study was restricted to subjects be-
longing to two racial/ethnic groups. At baseline, three
groups of 30 individuals were studied (N = 90): Latino di-
abetic controls, Latinos with DN and African Americans
with DN. Subjects were recruited from the inpatient and
outpatient services of two public hospitals in Southern
California, using the following inclusion criteria: 1) self-
defined Latino or African American; 2) age, 40–65 years;
3) meet the definition of DN or diabetic controls; and 4)
not undergoing maintenance dialysis.
The rationale and definitions used to define diabetic
controls and DN has been described previously and
were those established by the Family Investigation of
Nephropathy study [8, 24]. Briefly, diabetic controls were
defined as individuals with diabetes ≥10 years and spot
albumin/creatinine ratio <0.03 mg/mg. DN was defined
as: 1) renal biopsy evidence of DN with overt protein-
uria (urine protein/creatinine ratio ≥0.5 mg/mg) or; 2)
diabetes duration ≥10 years and protein creatinine ratio
≥2.5 mg/mg; or 3) diabetes duration ≥5 years, presence
of retinopathy, and protein/creatinine ratio ≥1.0 mg/mg.
The highest documented urine protein excretion in the
patient’s chart was used to determine eligibility. Of the
90 participants, 9 were positive for hepatitis C antibodies
(diabetic controls, N = 1 and DN, N = 8).
All enrolled subjects were scheduled for a clinic visit
at the General Clinical Research Center. The baseline
procedures have been described previously [8]. All sub-
jects were invited for a follow-up visit scheduled at least
9 months after the baseline evaluation. Identical study-
related procedures were followed at both the baseline and
follow-up visits. All the data thus collected were used to
determine the prevalence and/or severity of traditional
(age, gender, family history of premature cardiovascular
disease, hypertension, dyslipidemia, smoking, obesity),
renal-related (serum creatinine, calcium, phosphorus, in-
tact parathyroid hormone (iPTH, chemiluminescencent
immunometric assay, Nichols Institute, San Juan Capas-
trino, CA) and 1,25-dihydroxy vitamin D (extraction
chromatography radioreceptor assay, Quest Diagnostics
Nichols Institute, San Juan Capastrino, CA) levels) and
diabetes-related (glycosylated hemoglobin (HbA1c, high
pressure liquid chromatography, Tosho Medics, Inc., Fos-
ter City, CA) and duration of diabetes mellitus) risk
factors. Dyslipidemia was defined as either low-density
lipoprotein (LDL) cholesterol > 130 mg/dL or high-
density lipoprotein (HDL) cholesterol < 40 mg/dL or
treatment with lipid lowering medications at the base-
line visit. Serum phosphorus, iPTH and 1,25-dihydroxy
vitamin D levels were included as a part of the baseline
assessment only after the first nine patients had been en-
rolled; these data were available for 30 diabetic controls
and 51 subjects with DN. GFR was estimated using the
abbreviated Modification of Diet in Renal Disease equa-
tion [25].
Electron beam computed tomography
EBCT studies were performed on the same day as
each of the two clinic visits with a C-150 XL Ultra-
fast computed tomographic scanner (Imatron, South San
Francisco, CA). The scans were acquired by electrocar-
diographic triggering in end-systole, a method associated
with one of the lowest inter-scan variability [19, 20]. Both
the baseline and follow-up scans of all individuals were
retrieved, and the CAC was scored by a single, highly
experienced technician, using the Agatston method [17,
26].
Estimation of change in CAC score
In order to eliminate the dependence of the residual
inter-scan variability on the baseline CAC score, square
root transformation of the CAC scores was performed
prior to estimating progression of coronary calcification
[21, 22]. Two measures of progression were used. In the
first set of analyses, subjects were classified as “progres-
sors” or “non-progressors.” Using the data published by
Hokanson et al, “progressors” were defined as individu-
als with a difference of ≥ 2.5 units between the baseline
and final square root CAC scores [22]. Put differently,
a change of < 2.5 units between the baseline and final
square root CAC scores was deemed to be within the mar-
gins of error of estimation of CAC scores by EBCT scan-
ning and thus, attributed to inter-scan variability; such
subjects were classified as “non-progressors.” In a sec-
ond set of analyses, an annualized rate of change was
computed [(final square root CAC—baseline square root
CAC)/Follow-up interval in years] and was used as a con-
tinuous variable.
Statistical analyses
Data are expressed as mean and 95% confidence in-
terval (CI) for the mean; geometric means are reported
for variables that were not normally distributed (serum
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levels of LDL and HDL cholesterol, triglycerides, crea-
tinine, phosphorus and iPTH and CAC score). However,
since the change in CAC score included negative values,
computation of geometric means was not possible; these
variables are reported as median and interquartile range.
Paired comparisons of baseline and follow-up data were
performed using a paired t test or Wilcoxon signed-rank
test. Comparisons of unpaired data were performed using
a t test or Mann-Whitney U or Kruskall-Wallis test. Com-
parisons of proportions were made using a chi-square test
or Fisher’s exact test.
Multivariate analyses were performed to identify the
variables, other than the status of renal disease, signif-
icantly associated with progression of CAC. For these
analyses, two dummy variables were created for renal
disease—non-dialyzed DN (nephropathy at baseline, no
progression to ESRD, N = 45) and ESRD (nephropa-
thy at baseline, progression to ESRD, N = 15). Control-
ling for the presence of non-dialyzed DN, ESRD and
inter-scan interval, exploratory logistic regression anal-
yses were performed to identify the baseline variables to
be entered into a multivariate model from among the fol-
lowing: age, gender, ethnicity, measures of hypertension
(presence/absence of hypertension, systolic blood pres-
sure, number of anti-hypertensive medications), mea-
sures of dyslipidemia (presence/absence of dyslipidemia,
serum levels of total, LDL and HDL cholesterol and
triglycerides and treatment with lipid-lowering medica-
tions), family history of premature cardiovascular dis-
ease, history of coronary artery disease, smoking, body
mass index, renal-related risk factors (serum levels of
creatinine, calcium, phosphorus, iPTH, 1, 25 dihydroxy
vitamin D and albumin) and diabetes-related risk factors
(HbA1c and duration of diabetes mellitus). Variables that
attained a P value of ≤ 0.05 on the exploratory analyses
were sequentially entered into the baseline model that in-
cluded non-dialyzed DN, ESRD and inter-scan interval.
At each step, the improvement in the predictive value
of the model was tested by estimating the significance of
change in the −2 log likelihood ratio. Goodness of fit for
the final model was evaluated by Hosmer and Lemeshow
test.
Similar exploratory analyses were done using mul-
tivariate linear regression analyses for the annualized
change in square root CAC score. The baseline model
consisted of non-dialyzed DN and ESRD as predictor
variables. The variables with a P value ≤ 0.15 on ex-
ploratory analyses were sequentially fitted into the base-
line model and an improvement in predictive ability was
tested by the significance of change in the F-statistic.
Goodness of fit for the final model was evaluated by in-
specting the histogram of the residuals and the normal
P-P plot of regression standardized residuals.
Since data on repeat EBCT scans were not available for
22 subjects, sensitivity analyses were performed. Using
Table 1. Demographic and clinical characteristics of the study
population at baseline
Diabetic Diabetic
controls nephropathy
(N = 30) (N = 60)
Age years 54 (51, 56) 55 (53, 57)
Urine protein excretion g/day 7.2 (5.9, 8.5)
Urine albumin-creatinine ratio
mg/mg
0.01 (0.01, 0.02)
History of manifest coronary artery
disease %a
23% 25%
Duration of diabetes mellitus years 15 (12, 17) 17 (15, 19)
Hypertension prevalence %c 73% 97%
Dyslipidemia prevalence % 80% 85%
Current smokers % 17% 22%
Family history of premature
cardiovascular disease %
23% 14%
Follow-up interval between two
scans monthsb,c
14 (12, 16) 22 (19, 24)
Data are expressed as means with 95% confidence interval of mean or as% of
subjects in each group.
aDefined as positive history of angina (Rose questionnaire), myocardial
infarction, or revascularization at baseline visit.
bData reported for 23 diabetic controls and 45 diabetic nephropathy patients
who underwent repeat scanning.
cP < 0.05, for comparison between diabetic controls and diabetic nephropathy.
only the baseline variables, a multivariate linear regres-
sion model was built, using techniques similar to those de-
scribed above. This model was constructed without con-
sideration of progression to ESRD and after excluding
one individual with DN with an influential observation
for change in CAC scores. The best predictive model in-
corporated nephropathy status, serum creatinine, base-
line log-transformed CAC score, log CAC score-serum
creatinine interaction term, serum albumin and serum-
albumin-serum creatinine interaction term; this model
explained 73% of the variability in the annualized change
in CAC scores. The model was used to impute values for
change in CAC score in individuals without repeat scans.
The average inter-scan interval for the group (diabetic
controls or DN) was assigned to individuals with missing
data.
A P value of < 0.05 was considered significant for all
analyses.
RESULTS
Patient characteristics
The baseline characteristics of the study population are
summarized in Table 1 and the baseline and follow-up
data on risk factors are summarized in Table 2. At base-
line, diabetic controls had a significantly lower preva-
lence of hypertension, systolic and pulse pressures and
were taking fewer number of anti-hypertensive medica-
tions, compared to subjects with DN (Tables 1 and 2).
Furthermore, diabetic controls had significantly lower
levels of serum creatinine, phosphorus, and iPTH, and
higher GFR, 1,25 dihydroxy vitamin D and serum albu-
min, compared to subjects with DN (Table 2). All the
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Table 2. Distribution of traditional, renal-related, and diabetes-related risk factors in patients at baseline and follow-up
Diabetic controls Diabetic nephropathy
Baseline Baseline
Entire Complete Entire Complete
cohortb follow-upc Follow-upd cohortb follow-upc Follow-upd
Number of patients 30 23 23 60 45 45
Gender (M/F) 13/17 9/14 9/14 31/29 25/20 25/20
Race/ethnicity (Latinos/African Americans) 30/0 23/0 23/0 30/30 24/21 24/21
Hypertension
Systolic blood pressure mm Hg 140 (132,148)e 137 (128,146) 139 (129,148)e 158 (151,166) 159 (150,168) 158 (150,166)
Pulse pressure mm Hg 63 (55,70)e 60 (53,68) 60 (53,68)e 80 (73,86) 78 (70,86) 81 (73,89)
Antihypertensive medications number 1.2 (0.7,1.6)e 1.1 (0.6,1.6) 1.0 (0.4,1.5)e 3.0 (2.7,3.3) 2.8 (2.5,3.2) 3.0 (2.6,3.3)
Dyslipidemia
Total cholesterol mg/dL 198 (185,212) 196 (181,212) 199 (179,218) 200 (184,216) 195 (175,215)f 178 (159,192)
LDL cholesterol mg/dL 110 (93,128) 105 (85,126) 115 (102,132) 107 (98,120) 105 (91,117) 93 (83,105)
Triglycerides mg/dL 151 (117,195) 151 (110,209) 141 (100,199) 155 (132,186) 148 (120,182) 135 (115,158)
Body size
Body mass index kg/m2 31.6 (29.1,34.2) 31.7 (28,35) 31.9 (28.9,35.0) 31.1 (29.1,33.0) 32.4 (30.1,34.6) 31.4 (29.2,33.7)
Medications
ACEI/ARBb 63% 61% 48% 72% 73% 70%
HMG Co reductase inhibitors 33% 35% 33% 43% 42% 44%
Renal functiona
Serum creatinine mg/dL 0.7 (0.6,0.8)e 0.7 (0.6,0.8) 0.6 (0.6,0.7)e 2.2 (1.9,2.6) 1.7 (1.4,2.0)f 2.0 (1.6,2.6)
Estimated glomerular filtration 107 (96,118)e 110 (97,123) 120 (109,131)e 39 (32,46) 51 (41,62)f 44 (34,53)
rate mL/min/1.73m2
Serum albumin g/dL 3.7 (3.6,3.8)e 3.7 (3.6,3.8) 3.8 (3.7,3.9)e 3.1 (3.0,3.3) 3.2 (3.0,3.3) 3.3 (3.2,3.5)
Divalent ion metabolism
Serum calcium mg/dL 9.6 (9.5,9.7) 9.6 (9.5,9.8) 9.6 (9.4,9.8) 9.6 (9.5,9.8) 9.6 (9.4,9.8) 9.7 (9.6,9.9)
Serum phosphorus mg/dL 3.6 (3.5,3.8)e 3.6 (3.4,3.8) 3.7 (3.5,4.0)e 4.3 (4.0,4.6) 4.3 (3.9,4.6) 4.2 (3.9,4.5)
Serum parathyroid hormone pg/mL 44 (39,50)e 44 (38,52) 39 (33,47)e 131 (100,170) 129 (91,186) 129 (95,158)
Serum 1,25 dihydroxy vitamin D pg/mL 49 (42,55)e 48 (40,55)f 37 (33,41) 34 (30,37) 33 (29,37) 34 (29,39)
Coronary artery calcification
Prevalence 63%e 61% 65%e 93% 91% 91%
Agatston Score 11 (4,28)e 6 (3,16) 15 (6,35)e 57 (32,100) 54 (28,102)f 63 (37,107)
Data are expressed as geometric mean and 95% confidence intervals of mean; the data for all other variables are expressed as mean and 95% confidence interval of
mean.
aThe data on renal function excludes individuals who were undergoing maintenance dialysis at the time of follow-up visit.
bData from the baseline visit for all study participants.
cData from the baseline visit for subjects who underwent repeat EBCT scanning.
dData obtained at the time of the second EBCT scan for subjects who underwent repeat scanning.
eP < 0.05, for comparison between diabetic controls and diabetic nephropathy at the corresponding visit (baseline or follow-up).
fP < 0.05 for comparison between baseline and final visit for the corresponding group (diabetic controls or diabetic nephropathy).
above-mentioned variables, except 1,25 dihydroxy vita-
min D, continued to remain significantly different be-
tween the two groups upon follow-up.
Follow-up evaluations were completed in 68 subjects
(76%)—diabetic controls (N = 23), Latinos with DN
(N = 24) and African Americans with DN (N = 21)
(Fig. 1). Among diabetic controls, the following variables
differed at a P value of ≤ 0.10, between the 7 subjects
not available for the follow-up scan and 23 subjects with
complete follow up (without repeat scans vs. with repeat
scans): age (58 (53, 62) vs. 53 (50, 56) years, P = 0.10) and
baseline CAC score (68 (4, 107) vs. 6 (3, 16), P = 0.10).
Among individuals with DN, the variables were (15 with-
out repeat scan vs. 45 with repeat scan): age (59 (55, 63)
vs. 54 (52, 56) years, P = 0.008) and body mass index (27.2
(23.5,30.9) vs. 32.4 (30.1,34.6) kg/m2, P = 0.02).
Upon follow-up there was a significant decline in 1,25
dhydroxy vitamin D levels among diabetic controls (P =
0.03) and in serum levels of total cholesterol (P = 0.03)
among individuals with DN. Of the 45 subjects with DN,
15 (33%) had progressed to ESRD; these individuals had
a repeat scan performed at an interval of 22 (19, 26)
months and had been undergoing maintenance dialysis
for 13 (8, 18) months prior to the second scan. Of these
15 subjects, 11 were being treated with phosphate binders
at the time of evaluation—calcium-based binders, 6, se-
valemer hydrochloride, 4 and both, 1. Among the 30 DN
subjects not undergoing maintenance dialysis at follow-
up, there was a significant increase in serum creatinine
(P = 0.001) and decline in GFR (P = 0.005). There was
no significant difference between the baseline and final
value of any of the other risk factors listed in Table 2 in
either diabetic controls or DN subjects.
Progression of coronary artery calcification
At both baseline and follow-up, there was a signifi-
cantly lower prevalence of CAC among diabetic controls
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Baseline study cohort, N = 90
N = 60
N = 30)
N = 10
N = 9
N = 1)
(diabetic nephropathy, 
normoalbuminuric diabetics,
Dead
Type 2 diabetes, 
(diabetic nephropathy, 
normoalbuminuric diabetics,
N = 9
N = 5
N = 4)
Lost to follow-up 
/moved out of area
Type 2 diabetes, 
(diabetic nephropathy, 
normoalbuminuric diabetics,
N = 3
N = 1
N = 2)
Declined further participation
Type 2 diabetes, 
(diabetic nephropathy, 
normoalbuminuric diabetics,
N = 68
N = 45
N = 23)
Repeat EBCT scans done
Type 2 diabetes, 
(diabetic nephropathy, 
normoalbuminuric diabetics,
Fig. 1. Flow-diagram illustrating the follow-up status of the initial patient cohort.
compared to subjects with DN (Table 2). Furthermore,
the CAC score was significantly lower among diabetic
controls both at baseline (P < 0.001) and follow-up (P <
0.001), when compared to subjects with DN (Table 2).
Upon follow-up, using a change in ≥ 2.5 units in square
root CAC score, 13% (N = 3) of diabetic controls demon-
strated progression of CAC when compared to 47% of
subjects with DN (N = 21) (P = 0.006; odds ratio (OR)
for progression among DN subjects, 5.8 (95% CI: 1.5–
22.4)). The highest probability of progression of CAC was
observed among DN subjects that progressed to ESRD
(80%) followed by DN subjects who had not progressed
to ESRD (30%) followed by diabetic controls (13%) (P <
0.001) (Fig. 2A). Upon controlling the analyses for follow-
up interval, similar qualitative trends were identified (OR
for progression among DN, 3.0 (0.7,13.3)).
The annualized change in the square root CAC score
was significantly lower among diabetic controls (0.7
(−0.1, 1.1)) when compared to individuals with DN (1.4
(0.2, 2.7)) (P = 0.01). The magnitude of change in the an-
nualized square root CAC scores was highest among DN
subjects that progressed to ESRD followed by DN sub-
jects who did not progress to ESRD followed by diabetic
controls (P < 0.001) (Fig. 2B). Similar trends were ap-
parent using the absolute and percent annualized change
in untransformed CAC scores (diabetic controls vs. non-
dialyzed DN vs. ESRD: median absolute change/year - 0
(0, 5) vs. 18 (0, 98) vs. 136 (27, 324), P < 0.001 and median
percent change/year: 0% (−5,36) vs. 14% (0, 40) vs. 77%
(20, 258), P = 0.004).
Predictors of progression of CAC
Using logistic regression analyses and controlling for
the presence of non-dialyzed DN, ESRD and inter-scan
interval, age (OR for every 1 year increase, 1.13 (95%
CI: 1.02–1.27)) and baseline CAC score (OR for every
1 unit increase in Agatston score, 1.002 (1.000, 1.003))
were the significant predictors for progression of CAC.
The addition of age, but not the baseline CAC score, in
the model (non-dialyzed DN, ESRD, inter-scan interval)
resulted in a significant improvement in the predictive
value for the progression of CAC (Table 3).
Predictors of annualized change in CAC score
Using linear regression analyses and controlling for the
presence of non-dialyzed DN and ESRD, serum creati-
nine (P = 0.002) and the baseline log-transformed CAC
score (P = 0.003) were significant predictors of the annu-
alized change in square root CAC score. A significant
interaction between ESRD and serum creatinine was
identified; thus, for a given baseline serum creatinine,
individuals who progressed to ESRD had significantly
greater increase in the CAC scores than those who did
not. Other variables that achieved a P-value of < 0.15
were: HbA1c (P = 0.12), total cholesterol (P = 0.13) and
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Fig. 2. (A) Proportion of patients showing progression of coronary
artery calcification in each of the 3 groups—diabetic controls (N = 23),
nondialyzed DN (subjects with DN who did not progress to ESRD on
follow-up, N = 30), and DN-progressed to ESRD (subjects with DN
who progressed to ESRD on follow-up, N = 15). A subject was defined
as “progressor” if the difference between the square root transformed
final and baseline CAC score was≥2.5. The difference in the proportions
of patients with progressive CAC in the 3 groups was highly significant
(P < 0.001). (B) Box-plots illustrating the annualized change in square
root of the coronary artery calcification score among diabetic controls
(N = 23), nondialyzed subjects with diabetic nephropathy who did not
progress to end-stage renal disease (ESRD) (nondialyzed DN) (N =
30), and DN subjects who progressed to ESRD (DN-ESRD) (N = 15).
The bold line reflects the median score and the upper and lower lines
of the box represent the 25th and 75th percentile for the category. The
trend for increase in the change in CAC scores across the 3 categories
was statistically significant (P < 0.001).
serum phosphorus (P = 0.14). No significant effects of
ethnicity or use of lipid-lowering medications were iden-
tified on the rates of progression of CAC.
A multivariate linear regression model was built by se-
quentially adding the above variables into the baseline
model that included non-dialyzed DN and ESRD. The
sequential addition of serum creatinine (along with the
Table 3. Summary of the multivariate logistic regression analyses for
the predictors of the probability of progression of coronary artery
calcification
Odds ratio 95% CI
Nondialyzed DNa 1.18 0.20–6.78
Progression to ESRDa 19.85 2.52–156.7
Interscan interval, per 1 month increase 1.13 1.02–1.26
Age, per 1 year increase 1.13 1.02–1.27
aCompared to diabetic controls.
Table 4. Summary of the multiple linear regression analyses for the
predictors of the rate of progression of coronary artery calcification
Variable Coefficient Standard error P value
Progression to ESRD −3.04 1.30 0.02
Serum creatinine mg/dL 0.03 0.27 0.90
ESRD∗Serum creatinine 1.24 0.35 0.001
Baseline log CAC score 0.91 0.22 <0.001
interaction term, ESRD∗serum creatinine) and baseline
log-transformed CAC score led to significant improve-
ments in the predictive value of the regression model.
There were no further significant improvements in the
model by the addition of any of the other three vari-
ables (HbA1c, total cholesterol and serum phosphorus).
Furthermore, removing non-dialyzed DN from the final
model did not significantly alter the predictive value of
the model. The final model incorporating ESRD, serum
creatinine, ESRD∗serum creatinine interaction term and
log-transformed baseline CAC score explained 55% of
the variability in the progression of CAC scores in this co-
hort (Table 4). The multivariate linear regression model
explained 52% of the variability in the annualized change
in CAC score even upon excluding subjects who had CAC
scores of zero at both baseline and follow-up.
Sensitivity analyses
The effect of nephropathy status on progression of
CAC was re-estimated using the actual observations
for 68 individuals and imputed values for 22 sub-
jects. Controlling for inter-scan interval, the presence
of nephropathy was associated with significantly higher
odds for progression of CAC (OR, 4.0 (95% CI: 1.1,
15.2)). Similarly, the presence of DN was associated with
a significantly greater annualized change in square root
CAC scores (diabetic controls, 0.47 (−0.09, 1.69) and DN,
2.01 (0.48, 3.40), P = 0.002).
DISCUSSION
Among individuals with CKD, this is the first study to
evaluate the progression of CAC using a reliable method
that eliminates errors arising from inter-scan variability.
Furthermore, our study is the first to report that CAC is
more likely to be progressive among individuals with DN
when compared to duration-matched normoalbuminuric
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Table 5. Summary of the results of observational studies in subjects with chronic kidney disease that have examined the rates of progression of
coronary artery calcification
Patient number
Follow-up Scanning Interval Change in CAC score
Reference Baseline (% of baseline) protocol months Mean/median
Current study 60 45 (75%) EBCT,
end-systole
19a Progressors, 47%; progressed to ESRD, 80%; still
nondialyzed, 30%. Median annualized increase in
scores, 28%; progressed to ESRD, 77%; still
nondialyzed, 14%
ESRDc [1] 49 EBCT, 80% RR
interval
11–13 Baselinea and finala scores by age, respectively: 30–39,
42 and 36, 40–49 years—289 and 359; 50–59—756 and
1030; and 60–69—1720 and 1764
ESRD [2] 39 22 (56%) EBCT, 80% RR
interval
22b 50% with progression of CAC. CAC appeared in 2/12
with no baseline calcification; scores doubled in the
remaining 9/10 with baseline CAC
ESRD [11] 35 24 (69%) EBCT, 80% RR
interval
17b Progressors 75%; 50% had an increase in CAC scores
≥100 units
ESRD [12] 61 47 (77%) Multislice spiral
CT
12 Progressors, 45%; regressors, 26%; no change, 30%.
CAC score increased from 22.6a at baseline to 84a at
follow-up in entire cohort
Nondiabetic,
nondialyzed
CKD [10]
85 18 (21%) Multislice spiral
CT
8b 50% (N = 9) had no change in CAC (7 with baseline
CAC score = 0); the remaining subjects had 80%
increase in CAC score
aMedian.
bMean.
cNumerical increase in CAC score occurred in all subjects with repeat EBCT scans.
diabetic controls. Finally, progression of CAC was appar-
ent in almost a third of non-dialyzed individuals with DN,
suggesting that relatively rapid progressive vascular cal-
cification may begin before ESRD.
The availability of sensitive tools like EBCT has facil-
itated population-based studies of vascular calcification.
However, inter-scan variability in the CAC scores has lim-
ited its utility in longitudinal evaluations of calcification
burden [14–18]. Artifacts arising from the motion of coro-
nary arteries during cardiac systole constitute the major
source of error. Acquiring the images during end-systole
significantly reduces but does not eliminate this variabil-
ity [19, 20]. The magnitude of error from the residual
inter-scan variability seems to depend upon the baseline
CAC score and, when using untransformed CAC scores,
the direction of this error depends upon the method of
analyses [15, 21, 22]. Using the absolute change in un-
transformed CAC scores [final score—baseline score],
the inter-scan variability increases with increasing base-
line scores. On the other hand, using the percent change
from the baseline untransformed scores, the inter-scan
variability decreases with increasing baseline scores. The
method of analyses, thus, is critical in obtaining reliable
estimates of progression of CAC, particularly in popula-
tions with a high CAC burden as in subjects with CKD.
At least two different, reliable methods have been pro-
posed [21, 22]. While Bielak et have suggested using a
regression method for non-uniform differences to assess
change in CAC scores over time [21], Hokanson et al have
shown that square root transformation of CAC scores
eliminates the dependence of the error on the baseline
score [22]. Both these methods allow valid estimates of
the progression of CAC over a large range of CAC [22,
27]. We used the latter approach to account for the error
from inter-scan variability and this allowed us to obtain
reliable estimates of progression of CAC.
Using this method, our study demonstrates that among
individuals with type 2 diabetes mellitus, the presence
of nephropathy is associated with a significantly higher
probability of progression and a greater increase in CAC
scores. Two studies have reported the rates of progres-
sion among individuals with diabetes mellitus but the ef-
fect of presence of nephropathy has previously not been
evaluated [27, 28]. Using an identical method of analy-
ses, the probability of progression in our cohort of DN
over a period of 1.8 years (47%) was higher than pre-
viously reported among type 1 diabetics (21%) over 2.7
years [27]. The association of DN with more rapid pro-
gression of CAC among diabetic individuals, though not
surprising, has not been reported to date. Individuals with
DN have a significantly higher prevalence and severity of
CAC when compared to duration-matched diabetics with
normoalbuminuria [8]. A higher prevalence, severity and
a more rapid progression of CAC among individuals with
DN are consistent with the well-documented increase in
risk for cardiovascular events in this population [29]. If
future studies demonstrate that the CAC score has a sim-
ilar prognostic value among individuals with CKD as has
been shown in the general population [30], it may be pos-
sible to use the CAC score as a surrogate end-point for
studies that evaluate interventions to reduce the cardio-
vascular disease burden in this population.
Previous studies have reported progressive CAC in
45–100% of subjects with ESRD over 11–22 months of
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follow-up (Table 5); progression of CAC in 80% of our
middle-aged diabetic subjects who progressed to ESRD
are consistent with these findings (Table 5) [1, 2, 11, 12].
The rate of progression in our study subjects that pro-
gressed to ESRD is also similar to that reported earlier
(Table 5) [1, 2, 11, 12]. Upon controlling for nephropa-
thy status and progression to ESRD, serum creatinine
emerged as a significant predictor of the magnitude of
increase in CAC scores and there was a significant inter-
action between progression to ESRD and serum creati-
nine. Thus, for the same level of baseline serum creatinine,
the magnitude of increase in CAC score among individu-
als who progress to ESRD is expected to be significantly
greater than those that do not require maintenance dial-
ysis. These data are consistent with our previous observa-
tions that suggest that the risk factors for the progression
of CAC may differ at different stages of renal disease [8,
23].
Almost one-third of non-dialyzed subjects with DN
demonstrated progressive CAC over an interval of less
than two years. It is apparent that the proportion of pa-
tients with progressive CAC is significantly lower than
after attaining ESRD (Table 5) [1, 2, 11, 12]. Conversely,
CAC seems to progress over a short period of time in
a significant proportion of subjects with DN even be-
fore the need for dialysis, a finding heretofore not previ-
ously reported. These findings are consistent with those
reported among a subset of non-dialyzed non-diabetic
subjects with CKD [10]. Given the significant differences
in the method of analyses, a direct comparison of the rates
of progression of CAC in our study cohort to previous
publications involving subjects with CKD is not possible.
Not withstanding this limitation, it is apparent that the
progression of CAC in the pre-ESRD phase of diabetic
CKD many not be as rapid as in the ESRD phase of DN
(Table 5).
The probability of progression was significantly higher
in older individuals and the rate of progression was re-
lated to the severity of renal failure; no other variable was
independently related to change in CAC scores. Some,
though not all the studies in the general population and
one study in patients with ESRD, has demonstrated a
relationship between dyslipidemia and progression of
CAC; we were unable to demonstrate any such relation-
ship [11, 28, 31–33]. Furthermore, unlike several studies
in patients with ESRD, we were unable to demonstrate
any relationship between disordered mineral metabolism
and the progression of CAC [2, 12, 34].
This study has several limitations. First, the sample size
may have prevented us from identifying additional risk
factors for progression of CAC. Second, the follow-up
scans were not completed in all study subjects. However, a
follow-up rate of 76% is one of the highest achieved in ob-
servational studies of CAC among individuals with CKD
(Table 5). The demographics of the subjects who did not
undergo repeat EBCT scanning (older age, higher base-
line CAC scores) suggest that our study may have under-
estimated the progression of CAC. This observation is
supported by our sensitivity analyses which also indicate
that our inability to study all subjects at follow-up may
have led us to under-estimate the effect of nephropathy
on progression of CAC. Third, one-third of patients with
DN who underwent repeat scanning, were undergoing
maintenance dialysis at the time of follow-up evaluation.
This may have limited our ability to separate the risk fac-
tors that may be important in the progression of CAC
in the pre-dialysis phase of CKD and from those among
individuals with ESRD. Fourth, only a single measure-
ment of baseline variables evaluated as risk factors for
progression of CAC, was available for evaluation. Fifth,
the definition of progression of CAC was based upon pre-
viously published data from another site. This may have
compromised the precision of the cut-off value used to
define progression in this study. Since the acquisition of
EBCT scans in end-systole (as used in this study) is asso-
ciated with significantly lower inter-scan variability than
the conventional protocols, this approach may have led
us to under-estimate the proportion of progressors in the
study cohort. Finally, the rather short interval between
the scans, particularly among diabetic controls, may have
led us to under-estimate the prevalence of progressive
CAC.
CONCLUSION
Reliable estimates of the rates of progression of CAC
require attention to method of EBCT image acquisition
and the method of statistical analyses. Among individ-
uals with type 2 diabetes, the presence of nephropathy
is associated with a significantly higher probability and
rate of progression of CAC when compared to diabetes-
duration matched subjects with normoalbuminuria. The
rate of progression is particularly rapid among those indi-
viduals with DN who progress to ESRD; however, almost
a third of subjects with DN demonstrate progressive CAC
over a relatively short period of time before the need for
maintenance dialysis. Future studies need to identify the
factors that are associated with the progression of CAC
among individuals in the pre-dialysis phase of diabetic
CKD.
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